Jonathan Kerr
Jonathan Richard Kerr, BSc, MBBCh, MD, PhD, FRCPath, is a British researcher who became interested in ME/CFS after studying the consequences of Parvovirus B19 infection and finding that some of those infected went on to develop CFS. He has worked for St. George’s University of London[1] and as an Associate professor in the School of Medicine and Health Sciences at Universidad del Rosario, Bogotá, Colombia.[2] He returned to the UK in 2018, and practiced at the Department of Microbiology, Norfolk & Norwich University Hospitals NHS Foundation Trust.[3] Dr Kerr died in April 2023.[4]
Contents
Notable studies[edit | edit source]
- 1997, Parvovirus B19 and Chronic Fatigue Syndrome[5] - (Abstract)
- 2002, Chronic fatigue syndrome and arthralgia following parvovirus B19 infection[6] - (Abstract)
- 2005, Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome[7] - (Full Text)
- 2005, Association of chronic fatigue syndrome with human leucocyte antigen class II alleles[8] - (Full Text)
- 2007, Review - Current research priorities in chronic fatigue syndrome/myalgic encephalomyelitis: disease mechanisms, a diagnostic test and specific treatments[9] - (Full Text)
- 2008, Gene Expression Subtypes in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[10] - (Full Text)
- 2009, Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis[11] - (Full Text)
- 2010, Antibody to parvovirus B19 nonstructural protein is associated with chronic arthralgia in patients with chronic fatigue syndrome/myalgic encephalomyelitis[12] - (Full Text)
- 2014, Use of single-nucleotide polymorphisms (SNPs) to distinguish gene expression subtypes of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)[13] - (Abstract)
- 2016, Prevalencia de síntomas de fatiga crónica / encefalomielitis miálgica (SFC/EM) y su relación con factores ocupacionales en trabajadores en una empresa de vigilancia en Bogotá, Colombia
- 2016, MicroRNAs hsa-miR-99b, hsa-miR-330, hsa-miR-126 and hsa-miR-30c: Potential Diagnostic Biomarkers in Natural Killer (NK) Cells of Patients with Chronic Fatigue Syndrome (CFS)/ Myalgic Encephalomyelitis (ME)[14] - (Full Text)
- 2019, Review article - Epstein-Barr virus induced gene-2 upregulation identifies a particular subtype of Chronic Fatigue Syndrome / Myalgic Encephalomyelitis[15] - (Full text)
- 2019, Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors[3] - (Abstract)
Talks and interviews[edit | edit source]
- 2014, Dr. Kerr, I presume?
- 2015, Spoonie Radio - episode 14 - Jonathan Kerr
- 2018 Hope 4 ME + Fibro Nothern Ireland https://www.youtube.com/watch?v=c4SmVHAoSsQ
Invest in ME International ME Conference[edit | edit source]
- 2006, Speaker at the 1st Invest in ME International ME Conference on Viral and Human Gene Expression, development of diagnostic test, news of clinical trials[16] - (Video)
- 2007, Speaker at the 2nd Invest in ME International ME Conference on Case Study - Biomedical research (A view of a biomedical research team, how it is funded, what it needs, how it could be improved, what the future research would look like)[17] - (Video)
- 2008, Speaker at the 3rd Invest in ME International ME Conference on Gene Expression in ME/CFS: a means of Subtyping[18] - (Video)
- 2009, Speaker at the 4th Invest in ME International ME Conference on Severely-affected Sub Groups of ME/CFS[19] - DVD available
- 2010, Speaker at the 5th Invest in ME International ME Conference on Study of SNPs to determine subtype status in CFS patients[20] - DVD available
Online presence[edit | edit source]
See also[edit | edit source]
Learn more[edit | edit source]
References[edit | edit source]
- ↑ "UK Charity for Myalgic Encephalomyelitis Centre of Excellence for ME Blog". investinme.org. Retrieved August 3, 2019.
- ↑ http://www.urosario.edu.co/Profesores/Listado-de-profesores/K/Kerr-Jonathan-Ricardo/
- ↑ 3.03.1 Kerr, Jonathan R (July 17, 2019). "Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors". Journal of Clinical Pathology. 72 (10): 651–658. doi:10.1136/jclinpath-2019-205822. ISSN 0021-9746.
- ↑ "Invest in ME Research Group | Facebook". www.facebook.com. Retrieved April 20, 2023.
- ↑ Kerr, Jonathan R.; Barrett, Ann-Marie; Curran, MartinD.; Behan, Wilhelmina M.H.; Middleton, Derek; Behan, Peter O. (January 1997). "Parvovirus B19 and Chronic Fatigue Syndrome". Journal of Chronic Fatigue Syndrome. 3 (3): 101–107. doi:10.1300/J092v03n03_07. ISSN 1057-3321.
- ↑ Kerr, Jonathan R.; Bracewell, Janice; Laing, Ian; Mattey, Derek L.; Bernstein, Robert M.; Bruce, Ian N.; Tyrrell, David A.J. (March 2002). "Chronic fatigue syndrome and arthralgia following parvovirus B19 infection". The Journal of Rheumatology. 29 (3): 595–602. ISSN 0315-162X. PMID 11911112.
- ↑ Kaushik, N.; Fear, D.; Richards, S.C.M.; McDermott, C.R.; Nuwaysir, E.F.; Kellam, P.; Harrison, T.J.; Wilkinson, R.J.; Tyrrell, D.A.J.; Holgate, S.T.; Kerr, J.R. (August 1, 2005). "Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome". Journal of Clinical Pathology. 58 (8): 826–832. doi:10.1136/jcp.2005.025718. ISSN 0021-9746. PMC 1770875. PMID 16049284.
- ↑ Smith, J; Fritz, E L; Kerr, JR; Cleare, A J; Wessely, S; Mattey, D L (August 1, 2005). "Association of chronic fatigue syndrome with human leucocyte antigen class II alleles". Journal of Clinical Pathology. 58 (8): 860–863. doi:10.1136/jcp.2004.022681. ISSN 0021-9746. PMC 1770867. PMID 16049290.
- ↑ Kerr, J R; Christian, P; Hodgetts, A; Langford, P R; Devanur, L D; Petty, R; Burke, B; Sinclair, L I; Richards, S C M; Montgomery, J; McDermott, C R; Harrison, T J; Kellam, P; Nutt, D J; Holgate, S T; Collaborative Clinical Study Group (June 2, 2006). "Current research priorities in chronic fatigue syndrome/myalgic encephalomyelitis: disease mechanisms, a diagnostic test and specific treatments". Journal of Clinical Pathology. 60 (2): 113–116. doi:10.1136/jcp.2006.042374. ISSN 0021-9746.
- ↑ Kerr, Jonathan R; Petty, Robert; Burke, Beverley; Gough, John; Fear, David; Sinclair, Lindsey I; Mattey, Derek L; Richards, Selwyn C; Montgomery, Jane; Baldwin, Don A; Kellam, Paul; Harrison, Tim J; Griffin, George E; Main, Janice; Enlander, Derek; Nutt, David J; Holgate, Stephen T (April 15, 2008). "Gene Expression Subtypes in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis". The Journal of Infectious Diseases. 197 (8): 1171–1184. doi:10.1086/533453. PMID 18462164.
- ↑ Zhang, L.; Gough, J.; Christmas, D.; Mattey, D.L.; Richards, S.C.M.; Main, J.; Enlander, D.; Honeybourne, D.; Ayres, J.G.; Nutt, D.J.; Kerr, J.R. (February 1, 2010). "Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis". Journal of Clinical Pathology. 63 (2): 156–164. doi:10.1136/jcp.2009.072561. ISSN 0021-9746. PMC 2921262. PMID 19955554.
- ↑ Kerr, J.R.; Gough, J.; Richards, S.C.M.; Main, J.; Enlander, D.; McCreary, M.; Komaroff, A.L.; Chia, J.K. (April 1, 2010). "Antibody to parvovirus B19 nonstructural protein is associated with chronic arthralgia in patients with chronic fatigue syndrome/myalgic encephalomyelitis". Journal of General Virology. 91 (4): 893–897. doi:10.1099/vir.0.017590-0. ISSN 0022-1317.
- ↑ Shimosako, Nana; Kerr, Jonathan R. (2014), "Use of single-nucleotide polymorphisms (SNPs) to distinguish gene expression subtypes of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)", Journal of Clinical Pathology, 67 (12), doi:10.1136/jclinpath-2014-202597
- ↑ Petty, RobertD.; McCarthy, Nail E.; Le Dieu, Rifca; Kerr, Jonathan R. (2016), "MicroRNAs hsa-miR-99b, hsa-miR-330, hsa-miR-126 and hsa-miR-30c: Potential Diagnostic Biomarkers in Natural Killer (NK) Cells of Patients with Chronic Fatigue Syndrome (CFS)/ Myalgic Encephalomyelitis (ME)", PLOS One, doi:10.1371/journal.pone.0150904, PMID 26967895
- ↑ Kerr, Jonathan R. (February 2019). "Epstein-Barr virus induced gene-2 upregulation identifies a particular subtype of Chronic Fatigue Syndrome / Myalgic Encephalomyelitis". Frontiers in Pediatrics. 7: 59. doi:10.3389/fped.2019.00059.
- ↑ "IIMEC1". Invest in ME Research. Retrieved February 17, 2020.
- ↑ "IIMEC2". Invest in ME Research. Retrieved February 18, 2020.
- ↑ "IIMEC3". Invest in ME Research. Retrieved February 17, 2020.
- ↑ "IIMEC4". Invest in ME Research. Retrieved February 17, 2020.
- ↑ "IIMEC5 International ME Conference 2010". Invest in ME Research. Retrieved February 17, 2020.
myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.
antibodies Antibody/immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.
biomedical research basic medical research on organisms, such as humans or other living things, that helps increase medical knowledge. (Learn more: me-pedia.org)
biomedical research basic medical research on organisms, such as humans or other living things, that helps increase medical knowledge. (Learn more: me-pedia.org)
The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.
